Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 3, 2000, Pages 207-212

  Warren, Katherine E ^a   Patel, Mahendra C ^a   McCully, Cynthia M ^a   Montuenga, Luis M ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Blood brain barrier; Cyclosporin A; Doxorubicin; Multidrug resistance; P glycoprotein

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACACA; NONHUMAN; PRIORITY JOURNAL;

EID: 0033977493     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050031     Document Type: Article

References (31)

1. 1. Stewart PA, Hayakawa K, Farrell CL (1994) Quantitation of blood-brain barrier ultrastructure. Microsc Res Tech 27: 516-527
2. 2. Brightman MW (1977) Morphology of blood-brain interfaces. Exp Eye Res [Suppl] 25: 1-25
3. 3. Thiebaut F, Tsuruo T, Hamada H, et al (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37: 159-164
4. 4. Cordon-Cardo C, O'Brien JP, Casals D, et al (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698
5. 5. Schinkel AH, Mol CA, Wagenaar E, et al (1995) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A: 1295-1298
6. 6. Tatsuta T, Naito M, Oh-hara T, et al (1992) Physiological function of P-glycoprotein in brain capillary endothelial cells. Proc Am Assoc Cancer Res 33: 467
7. 7. Fojo A, Akiyama S, Gottesman MM, et al (1985) Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007
8. 8. Willingham MC, Cornwell MM, Cardarelli CO, et al (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 5941-5946
9. 9. Asperen J van, Schinkel AH, Beijnen JH, et al (1996) Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994-999
10. 3H-vinblastine binding to plasma membranes of multidrug resistant and sensitive cells. Proc Am Assoc Cancer Res 31: 407
11. 11. Sikic BI (1997) Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34 [Suppl 5]: 40-47
12. 12. Osieka R, Seeber S, Pannenbacker R, et al (1986) Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 18: 198-202
13. 13. Slater LM, Sweet P, Stupecky M, et al (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77: 1405-1408
14. 14. Chan H, Thorner P, Weitzmann S, et al (1992) Cyclosporin A for reversal of multidrug resistance in childhood malignancies. Proc Am Assoc Cancer Res 33: 478
15. 15. Samuels B, Ratain M, Mick R, et al (1991) Phase I trial of multidrug resistance modulation with cyclosporin A. Proc Am Assoc Cancer Res 32: 195
16. 16. Thiessen J, Bunting P, Bjarnason G, et al (1992) Cyclosporin A (CyA) modulation of doxorubicin (D): Pharmacokinetics, response, evaluation of the MTD. Proc Am Assoc Cancer Res 33: A2798
17. 17. Yahanda AM, Adler KM, Fisher GM, et al (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624-1634
18. 18. Hegewisch-Becker S (1996) MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance pheno-type. Leukemia 10 [Suppl 3]: S32-S38
19. 19. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington DC
20. 20. McCully CL, Balis FM, Bacher J, et al (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40: 250-255
21. 21. Cordon-Cardo C, O'Brien JP, Casals BD, et al (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287
22. 22. Georges E, Bradley G, Gariepy J, et al (1990) Detection of P-glycoprotein isoforms by gene specific monoclonal antibodies. Proc Natl Acad Sci U S A 87: 152-156
23. 23. Scheper RJ, Bulte JW, Brakkee JG, et al (1988) Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 42: 389-394
24. 24. Ford JM (1995) Modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 337-361
25. 25. Arboix M, Gonzalez-Paz O, Colombo T, et al (1997) Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther 281: 1226-1230
26. 26. Burgio DE, Gosland MP, McNamara PJ (1996) Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. Biochem Pharmacol 51: 987-992
27. 27. Lemaire M, Bruelisauer A, Guntz P, et al (1996) Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 38: 481-486
28. 28. Fisher GA, Sikic BI (1995) Clinical studies with modulators of drug resistance. Hematol Oncol Clin North Am 9: 363-382
29. 29. Tew K (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320
30. 30. Nooter K, Sloter G (1996) Molecular mechanisms of multidrug resistance in cancer chemotherapy. Path Res Pract 192: 768-780
31. 31. Cole SPC, Bhardwaj G, Gerlach JH, et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654